Description: <p><b>Eurycomanone</b> — Eurycomanone is a highly oxygenated quassinoid diterpenoid from <i>Eurycoma longifolia</i> Jack, commonly known as tongkat ali or longjack. It is a small-molecule plant secondary metabolite and should be classified as a natural-product quassinoid, not as an essential oil constituent. It is best indexed separately from crude <i>Eurycoma longifolia</i> extract because isolated eurycomanone has specific anticancer mechanisms, while commercial tongkat ali extracts have variable composition and separate androgenic/supplement safety issues.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of intrinsic apoptosis through p53 activation, ↑ Bax, ↓ Bcl-2, and downstream caspase activation.</li>
<li>Suppression of cancer-cell proliferation, clonogenic growth, and cell-cycle progression in multiple in-vitro cancer models.</li>
<li>Autophagy inhibition in colon cancer through mTOR activation, ↓ LC3-II, and reduced autophagosome formation.</li>
<li>Anti-invasive and anti-EMT activity in NSCLC models through inhibition of TGF-β1-linked Smad and non-Smad signaling, including Akt-linked effects and ↓ MMP-2 secretion.</li>
<li>Anti-angiogenic signaling in colon cancer models, mainly as a preclinical tumor-support pathway effect.</li>
<li>Context-dependent modulation of steroidogenic pathways, including aromatase and phosphodiesterase inhibition; this is pharmacologically relevant but not a core anticancer mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral exposure is plausible but constrained by formulation, extract matrix, and rapid disposition; pure eurycomanone and standardized <i>Eurycoma</i> extracts are not interchangeable for PK interpretation. Cancer evidence is mostly based on isolated compound exposure in cell culture, so achievable systemic concentrations remain a major translation constraint.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Several anticancer studies use micromolar or microgram-per-mL concentrations that may exceed typical nutraceutical oral exposure. Non-toxic anti-invasive NSCLC work used sub-cytotoxic micromolar doses, but clinical relevance remains uncertain without cancer PK/PD data. This is concentration-driven pharmacology, not field-based or trigger-based therapy.</p>
<p><b>Clinical evidence status:</b> Preclinical only for cancer. No cancer RCTs, no oncology deployment, and no regulatory approval as an anticancer drug. Human studies and supplement safety data relate mainly to <i>Eurycoma longifolia</i> extracts for male-health indications, not isolated eurycomanone for cancer.</p>
<h3>Eurycomanone Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>p53 Bax Bcl-2 mitochondrial apoptosis</td>
<td>↑ p53, ↑ Bax, ↓ Bcl-2, ↑ apoptosis</td>
<td>Relative sparing reported in some non-malignant comparator cells, but not fully established</td>
<td>G</td>
<td>Intrinsic apoptotic killing</td>
<td>Most central anticancer mechanism; reported in HepG2, cervical carcinoma, breast cancer, and leukemia-related models.</td>
</tr>
<tr>
<td>2</td>
<td>Caspase 9 caspase 3 apoptosis execution</td>
<td>↑ caspase-dependent apoptosis</td>
<td>Model-dependent selectivity</td>
<td>G</td>
<td>Execution-phase apoptosis</td>
<td>Fits mitochondrial apoptosis pattern; strongest when paired with p53 Bax Bcl-2 findings.</td>
</tr>
<tr>
<td>3</td>
<td>Proliferation and cell-cycle control</td>
<td>↓ proliferation, ↓ colony formation, cell-cycle arrest (model-dependent)</td>
<td>Less defined</td>
<td>G</td>
<td>Growth suppression</td>
<td>Broad preclinical anticancer signal, but potency and selectivity vary by cell line and assay.</td>
</tr>
<tr>
<td>4</td>
<td>mTOR autophagy inhibition</td>
<td>↑ mTOR signaling, ↓ LC3-II, ↓ GFP-LC3 puncta, ↓ protective autophagy</td>
<td>Not well characterized</td>
<td>R/G</td>
<td>Reduced survival autophagy</td>
<td>Colon cancer data suggest autophagy supports survival under eurycomanone stress; autophagy inhibition strengthens growth inhibition.</td>
</tr>
<tr>
<td>5</td>
<td>TGF-β1 EMT Smad signaling</td>
<td>↓ EMT, ↓ migration, ↓ invasion, ↑ E-cadherin or ↓ N-cadherin depending on cell line</td>
<td>Not established</td>
<td>G</td>
<td>Anti-invasive effect</td>
<td>Relevant to metastatic NSCLC behavior; effects differ between A549 and Calu-1 cells.</td>
</tr>
<tr>
<td>6</td>
<td>Akt non-Smad EMT signaling</td>
<td>↓ Akt-linked EMT signaling (context-dependent)</td>
<td>Not established</td>
<td>R/G</td>
<td>Migration and invasion suppression</td>
<td>Secondary to TGF-β1 anti-EMT mechanism; therapeutic leverage is anti-metastatic rather than direct cytotoxicity.</td>
</tr>
<tr>
<td>7</td>
<td>MMP-2 extracellular matrix invasion</td>
<td>↓ MMP-2 secretion, ↓ Matrigel invasion</td>
<td>Not established</td>
<td>G</td>
<td>Reduced matrix invasion</td>
<td>Supports anti-metastatic classification in NSCLC models.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis support signaling</td>
<td>↓ angiogenesis-associated activity in colon cancer models</td>
<td>Normal endothelial-cell selectivity not fully defined</td>
<td>G</td>
<td>Reduced tumor-support signaling</td>
<td>Preclinical pathway; not sufficient alone to classify as a validated anti-angiogenic therapy.</td>
</tr>
<tr>
<td>9</td>
<td>A549 tumor marker proteins</td>
<td>↓ prohibitin, ↓ annexin 1, ↓ ERp28 reported</td>
<td>Not established</td>
<td>G</td>
<td>Proteomic tumor phenotype modulation</td>
<td>Useful as supporting mechanistic evidence in lung cancer, but less central than apoptosis or EMT inhibition.</td>
</tr>
<tr>
<td>10</td>
<td>ROS NRF2 oxidative stress</td>
<td>Insufficient direct eurycomanone cancer evidence for core ranking</td>
<td><i>Eurycoma</i> extract shows antioxidant effects in non-cancer models</td>
<td>G</td>
<td>Context-dependent stress modulation</td>
<td>ROS or NRF2 is NOT a primary cancer mechanism.</td>
</tr>
<tr>
<td>11</td>
<td>Steroidogenesis aromatase phosphodiesterase</td>
<td>Potential hormone-context relevance, not a direct anticancer axis</td>
<td>↑ androgenic or fertility-related signaling in reproductive models</td>
<td>G</td>
<td>Endocrine pharmacology</td>
<td>Important safety and interpretation constraint, especially for hormone-sensitive disease contexts.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>In-vitro potency may not match oral systemic exposure</td>
<td>Supplement safety is extract-dependent; liver injury is a possible rare concern</td>
<td>G</td>
<td>Limits clinical use</td>
<td>Main constraints are oral PK, extract variability, lack of cancer trials, dose ceiling, possible hepatotoxicity signal, and uncertain normal-cell therapeutic window.</td>
</tr>
</tbody>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>